Moody Lynn & Lieberson LLC Decreases Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Moody Lynn & Lieberson LLC reduced its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 12.2% during the 4th quarter, HoldingsChannel.com reports. The firm owned 57,223 shares of the pharmaceutical company’s stock after selling 7,984 shares during the period. Vertex Pharmaceuticals makes up 1.4% of Moody Lynn & Lieberson LLC’s investment portfolio, making the stock its 24th largest position. Moody Lynn & Lieberson LLC’s holdings in Vertex Pharmaceuticals were worth $23,044,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Daymark Wealth Partners LLC lifted its stake in Vertex Pharmaceuticals by 38.9% in the second quarter. Daymark Wealth Partners LLC now owns 782 shares of the pharmaceutical company’s stock valued at $367,000 after buying an additional 219 shares during the last quarter. Susquehanna Fundamental Investments LLC acquired a new stake in shares of Vertex Pharmaceuticals during the second quarter worth about $21,008,000. Peloton Wealth Strategists acquired a new position in Vertex Pharmaceuticals in the 2nd quarter valued at about $270,000. Raab & Moskowitz Asset Management LLC lifted its position in Vertex Pharmaceuticals by 2.8% during the 2nd quarter. Raab & Moskowitz Asset Management LLC now owns 1,786 shares of the pharmaceutical company’s stock worth $837,000 after acquiring an additional 48 shares during the period. Finally, Driehaus Capital Management LLC lifted its position in Vertex Pharmaceuticals by 25.2% during the 2nd quarter. Driehaus Capital Management LLC now owns 1,169 shares of the pharmaceutical company’s stock worth $548,000 after acquiring an additional 235 shares during the period. Institutional investors and hedge funds own 90.96% of the company’s stock.

Vertex Pharmaceuticals Stock Performance

NASDAQ:VRTX opened at $439.62 on Friday. Vertex Pharmaceuticals Incorporated has a 1-year low of $377.85 and a 1-year high of $519.88. The firm has a 50 day simple moving average of $435.36 and a 200-day simple moving average of $464.66. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.47 and a quick ratio of 2.20.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its earnings results on Monday, November 4th. The pharmaceutical company reported $4.38 earnings per share for the quarter, topping the consensus estimate of $3.61 by $0.77. Vertex Pharmaceuticals had a negative return on equity of 1.91% and a negative net margin of 4.52%. The firm had revenue of $2.77 billion for the quarter, compared to the consensus estimate of $2.69 billion. During the same period in the prior year, the business posted $3.67 earnings per share. The firm’s revenue for the quarter was up 11.6% compared to the same quarter last year. On average, equities research analysts anticipate that Vertex Pharmaceuticals Incorporated will post -1.9 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have recently commented on VRTX shares. Scotiabank upped their price target on Vertex Pharmaceuticals from $426.00 to $430.00 and gave the stock a “sector perform” rating in a research note on Monday, December 23rd. Truist Financial lowered their price objective on Vertex Pharmaceuticals from $550.00 to $460.00 and set a “buy” rating on the stock in a report on Monday, December 23rd. Stifel Nicolaus boosted their target price on Vertex Pharmaceuticals from $490.00 to $494.00 and gave the stock a “hold” rating in a research report on Monday, December 16th. Oppenheimer cut Vertex Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Thursday, December 19th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Vertex Pharmaceuticals in a report on Friday, December 20th. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Vertex Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $494.84.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.